LOCHOLEST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOCHOLEST (LOCHOLEST).
Locholest is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting fecal excretion. This leads to increased hepatic conversion of cholesterol to bile acids, reducing serum LDL cholesterol.
| Metabolism | Not absorbed systemically; acts locally in gastrointestinal tract. No hepatic metabolism. |
| Excretion | Primarily fecal (biliary) as unchanged drug; renal excretion <5%. |
| Half-life | Terminal elimination half-life is approximately 19 hours (range 14-47 hours) for patients with normal renal function; accumulation occurs with once-daily dosing. |
| Protein binding | >95% bound to plasma proteins. |
| Volume of Distribution | Vd approximately 5.4 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability is 30% (range 12-60%) due to extensive first-pass metabolism. |
| Onset of Action | Oral: 2 weeks for initial reduction in LDL-C; maximal effect by 4-6 weeks. |
| Duration of Action | Duration of effect is sustained with continued therapy; after discontinuation, lipid levels return to baseline within 6 weeks. |
Initial dose: 10-20 mg orally once daily, taken in the evening. Titrate as tolerated every 4 weeks to a maximum of 80 mg once daily.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl >30 mL/min). In severe renal impairment (CrCl <30 mL/min), not on dialysis: maximum dose 20 mg daily; on dialysis: maximum dose 20 mg daily (administer after dialysis). |
| Liver impairment | Contraindicated in active liver disease or unexplained persistent transaminase elevations. For Child-Pugh Class A: reduce dose; maximum 20 mg daily. Child-Pugh Class B: maximum 10 mg daily. Child-Pugh Class C: use not recommended. |
| Pediatric use | For heterozygous familial hypercholesterolemia (HeFH) in children ≥10 years: initial dose 10 mg once daily; titrate to 20 mg after 4 weeks; maximum 40 mg daily. For children <10 years: safety and efficacy not established. |
| Geriatric use | Elderly patients (≥65 years) may be more susceptible to myopathy; start at lower end of dosing range (10 mg daily) and titrate cautiously. No specific dose adjustment required based on age alone, but monitor renal function and drug interactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOCHOLEST (LOCHOLEST).
| Breastfeeding | Cholestyramine is not absorbed systemically, so excretion into breast milk is negligible. No M/P ratio available; considered compatible with breastfeeding. Caution advised due to potential interference with maternal vitamin K absorption, which could affect infant coagulation. |
| Teratogenic Risk | Locholest (cholestyramine) is a non-absorbable bile acid sequestrant. No known teratogenic risk; reduced absorption of fat-soluble vitamins may occur, potentially affecting fetal development if deficiency arises. No specific fetal risks reported from direct drug exposure. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Complete biliary obstruction","Hypersensitivity to any component of the formulation"]
| Precautions | ["May cause hypertriglyceridemia, especially in patients with pre-existing hypertriglyceridemia","Risk of vitamin K deficiency and bleeding due to fat malabsorption","May impair absorption of fat-soluble vitamins (A, D, E, K)","Chronic use may lead to hyperchloremic metabolic acidosis, especially in children and smaller adults","May bind other drugs; administer other drugs at least 1 hour before or 4-6 hours after Locholest"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal prothrombin time and INR for vitamin K deficiency; assess for signs of fat-soluble vitamin deficiency (A, D, E, K). Periodic fetal growth assessment with ultrasound. Monitor maternal lipid levels and gastrointestinal tolerability. |
| Fertility Effects | No direct effects on fertility reported. Chronic use may lead to vitamin deficiencies (e.g., folate), which could indirectly affect reproductive outcomes. No adverse impact on male or female fertility in humans. |